OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.21 USD | -5.96% |
|
-5.96% | +46.36% |
| 05-08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| 05-08 | Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +46.36% | 70.1M | - | ||
| +17.28% | 79.84B | A | ||
| +11.81% | 9.12B | A- | ||
| +42.52% | 4.46B | - | ||
| -22.31% | 4.42B | A- | ||
| +10.76% | 4.13B | B- | ||
| +7.34% | 2.18B | B | ||
| -27.16% | 2.17B | C- | ||
| +11.24% | 2.01B | - | - | |
| -43.24% | 1.77B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORX Stock
- ORXOY Stock
- Ratings Orexo AB